Fresenius SE & Co. KGaA (FRE) - Total Assets
Based on the latest financial reports, Fresenius SE & Co. KGaA (FRE) holds total assets worth €42.46 Billion EUR (≈ $49.64 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore FRE operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Fresenius SE & Co. KGaA - Total Assets Trend (2002–2024)
This chart illustrates how Fresenius SE & Co. KGaA's total assets have evolved over time, based on quarterly financial data. See FRE total equity for net asset value and shareholders' equity analysis.
Fresenius SE & Co. KGaA - Asset Composition Analysis
Current Asset Composition (December 2024)
Fresenius SE & Co. KGaA's total assets of €42.46 Billion consist of 26.3% current assets and 73.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.7% |
| Accounts Receivable | €5.19 Billion | 11.9% |
| Inventory | €2.57 Billion | 5.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.42 Billion | 5.6% |
| Goodwill | €15.09 Billion | 34.6% |
Asset Composition Trend (2002–2024)
This chart illustrates how Fresenius SE & Co. KGaA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Fresenius SE & Co. KGaA (FRE) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fresenius SE & Co. KGaA's current assets represent 26.3% of total assets in 2024, a decrease from 30.8% in 2002.
- Cash Position: Cash and equivalents constituted 4.7% of total assets in 2024, up from 1.8% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, a decrease from 44.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 34.6% of total assets.
Fresenius SE & Co. KGaA Competitors by Total Assets
Key competitors of Fresenius SE & Co. KGaA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Apollo Hospitals Enterprise Limited
NSE:APOLLOHOSP
|
India | Rs219.50 Billion |
|
Sienna Senior Living Inc
TO:SIA
|
Canada | CA$2.35 Billion |
|
Mitra Keluarga Karyasehat Tbk PT
JK:MIKA
|
Indonesia | Rp9.64 Trillion |
|
Chularat Hospital Public Company Limited
BK:CHG
|
Thailand | ฿10.61 Billion |
|
Hospital Mater Dei S.A
SA:MATD3
|
Brazil | R$4.33 Billion |
|
Lippo Karawaci Tbk
JK:LPKR
|
Indonesia | Rp48.70 Trillion |
|
ARRAIL GROUP LTD.
F:I1D
|
Germany | €3.16 Billion |
|
Premier Health of America Inc
V:PHA
|
Canada | CA$42.63 Million |
Fresenius SE & Co. KGaA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.26 | 1.36 | 1.19 |
| Quick Ratio | 0.99 | 1.05 | 0.89 |
| Cash Ratio | 0.25 | 0.18 | 0.00 |
| Working Capital | €2.50 Billion | €2.95 Billion | €2.56 Billion |
Fresenius SE & Co. KGaA - Advanced Valuation Insights
This section examines the relationship between Fresenius SE & Co. KGaA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.55 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | -3.8% |
| Total Assets | €43.55 Billion |
| Market Capitalization | $28.22 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Fresenius SE & Co. KGaA's assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Fresenius SE & Co. KGaA's assets decreased by 3.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Fresenius SE & Co. KGaA (2002–2024)
The table below shows the annual total assets of Fresenius SE & Co. KGaA from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €43.55 Billion ≈ $50.91 Billion |
-3.83% |
| 2023-12-31 | €45.28 Billion ≈ $52.94 Billion |
-40.74% |
| 2022-12-31 | €76.42 Billion ≈ $89.34 Billion |
+6.19% |
| 2021-12-31 | €71.96 Billion ≈ $84.13 Billion |
+7.98% |
| 2020-12-31 | €66.65 Billion ≈ $77.92 Billion |
-0.54% |
| 2019-12-31 | €67.01 Billion ≈ $78.34 Billion |
+18.17% |
| 2018-12-31 | €56.70 Billion ≈ $66.29 Billion |
+6.72% |
| 2017-12-31 | €53.13 Billion ≈ $62.12 Billion |
+14.39% |
| 2016-12-31 | €46.45 Billion ≈ $54.30 Billion |
+7.59% |
| 2015-12-31 | €43.17 Billion ≈ $50.47 Billion |
+8.20% |
| 2014-12-31 | €39.90 Billion ≈ $46.64 Billion |
+21.79% |
| 2013-12-31 | €32.76 Billion ≈ $38.30 Billion |
+6.83% |
| 2012-12-31 | €30.66 Billion ≈ $35.85 Billion |
+16.50% |
| 2011-12-31 | €26.32 Billion ≈ $30.77 Billion |
+11.64% |
| 2010-12-31 | €23.58 Billion ≈ $27.56 Billion |
+12.91% |
| 2009-12-31 | €20.88 Billion ≈ $24.41 Billion |
+1.65% |
| 2008-12-31 | €20.54 Billion ≈ $24.02 Billion |
+34.06% |
| 2007-12-31 | €15.32 Billion ≈ $17.92 Billion |
+2.00% |
| 2006-12-31 | €15.02 Billion ≈ $17.56 Billion |
+29.58% |
| 2005-12-31 | €11.59 Billion ≈ $13.55 Billion |
+41.60% |
| 2004-12-31 | €8.19 Billion ≈ $9.57 Billion |
-1.90% |
| 2003-12-31 | €8.35 Billion ≈ $9.76 Billion |
-6.37% |
| 2002-12-31 | €8.91 Billion ≈ $10.42 Billion |
-- |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machin… Read more